SENTI-101

N/A

Report date: 2023/04/23 16:11:33

Base Information

Drug NameSENTI-101
Drug Alias NameA Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21 (Senti Biosciences)SENTI-101
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionInterleukin-12 receptor stimulantsInterleukin 21 Receptor agonists
TargetsInterleukin-12 receptorInterleukin 21 Receptor
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSenti Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesSenti Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A